RxDoctor Payments Data

Thomas Kim, MD

Cardiovascular Disease · Kissimmee, FLNPI 1194726844

Payments from drug & device makers

$2,597in general payments, 2019–2025

Across 99 payments — averaging $26.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$575
  • Boston Scientific$257
  • Biotronik Inc.$256
  • Medtronic$235
  • Johnson & Johnson$179
  • AstraZeneca$148
  • plus $945 from 16 others

What the payments were for

  • Travel & lodging$2379%
  • Food & beverage$2,24787%
  • Education$1134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,597 in reported general payments places this provider in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$522,189
Medicare patients
1,243
Services billed
6,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban423$523,211
XareltoRivaroxaban192$236,407
EntrestoSacubitril/Valsartan72$125,964
FarxigaDapagliflozin Propanediol56$82,959
JardianceEmpagliflozin62$79,412
Repatha SureclickEvolocumab18$22,756
Flecainide Acetate115$6,730
Ranolazine ErRanolazine52$6,323
Dabigatran EtexilateDabigatran Etexilate Mesylate20$6,307
Metoprolol Succinate380$5,909
Atorvastatin Calcium574$5,907
Amiodarone Hcl141$4,348
Losartan Potassium254$3,236
Midodrine Hcl32$3,089
Ezetimibe97$2,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$108$523,211423 claims
Johnson & JohnsonXarelto$179$236,407192 claims
AstraZenecaFarxiga$148$82,95956 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →